Abstract：Objective: To investigate the effect of dexmedetomidine (DEX) on perioperative platelet activity and cellular immunity for patients undergoing colon cancer radical surgery. Methods: 60 patients undergoing colon cancer radical surgery were assigned into two groups using random table method: DEX group (n=30) and control group (n=30). DEX group was given intravenous infusion of DEX with loading dose of 1μg/kg 10 min before anesthesia induction, and then at 0.5μg·kg-1·h-1 till completing the surgery; the control group was given intravenous infusion of 0.9% sodium chloride. The levels of P-selection (CD62P), glycoprotein(GP) II b/III a, IgM, IgG, IgA, CD3+, CD4+, CD8+, and CD4+/CD8+ at 5 min before anesthesia induction (T0), immediately after the surgery (T1), 12h after the surgery (T2), 24h after the surgery (T3) were compared between the two groups. And the adverse events of the two groups were compared. Results: There were no differences in the levels of CD62P, GP II b/III a, IgM, IgG, IgA, CD3+, CD4+, CD8+ and CD4+/8+ at T0 between the two groups (P>0.05). CD62P and GP II b/III at T1, T2 and T3 of the two groups were significantly higher those at T0 and their levels of the control group were significantly higher than those of DEX group (P<0.05). IgM, IgG, IgA, CD3+, CD4+, CD8+ and CD4+/8+ of the DEX group at T1, T2 and T3 were similar to those at T0. IgM, IgG, IgA, CD3+, CD4+, CD8+ and CD4+/8+ of the control group at T1, T2 and T3 were significantly lower than those at T0, and lower than those of the DEX group (P<0.05), while the levels of CD8+ strongly increased and were higher than those of the control group (P<0.05). There were no difference in the adverse events rates between the two groups (P>0.05). Conclusions: DEX can inhibit platelet hyperactivation and stabilize immune function of patients undergoing radical resection of colon cancer without increasing adverse reactions. It has certain clinical value in preventing and treating perioperative hematogenous metastasis of tumor cells in patients undergoing radical resection of colon cancer.
曹丙玉,许晓群. 右美托咪定对结肠癌根治术患者围术期血小板活性和免疫功能的影响[J]. 河北医学, 2018, 24(10): 1731-1735.
CAO Bingyu, et al. Effect of Dexmedetomidine on Perioperative Platelet Activity and Cellular Immunity Function for Patients Undergoing Colon Cancer Radical Surgery. HeBei Med, 2018, 24(10): 1731-1735.
[1] Issa I A, Noureddine M. Colorectal cancer screening: an updated review of the available options[J]. World Gastroenterol, 2017, 23(28):5086~5096.
[2] Vermeer NC, Snijders HS, Holman FA, et al. Colorectal cancer screening: systematic review of screen-related morbidity and mortality[J]. Cancer Treat Rev, 2017, 54:87~98.
[3] 闫怀军,张晓云,王京鹏,等.不同全麻方式对腹腔镜结肠癌切除术患者围麻醉期T淋巴细胞亚群的影响研究[J].中国内镜杂志,2017,23(9):48~51.
[4] Yeon KS, Kyu KN, Hyuk BS, et al. Effects of postoperative pain management on immune function after laparoscopic resection of colorectal cancer:a randomized study[J]. Medicine, 2016, 95(19):e3602.
[5] 洪彬源,刘洪珍,潘晓梅,等.多模式的镇痛方法对结肠癌根治术患者的免疫功能的影响[J].免疫学杂志,2016(4):351~355.
[6] 徐巧敏,吴玮凌,章玲宾,等.右美托咪定对高脂血症冠心病患者腹腔镜手术围术期血小板活化的影响[J].中国临床药理学与治疗学,2017,22(11):1269~1273.
[7] Abrahao A, Karim S, Colwell B, et al. The predictive effect of primary tumour location in the treatment of metastatic colorectal cancer: a Canadian consensus statement[J]. Curr Oncol, 2017,24(6):390~400.
[8] 桂秀娟,林绍强.血小板C型凝集素样受体-2参与肿瘤血行转移的研究进展[J].肿瘤,2017,37(8):883~888.
[9] Davy A, Fessler J, Fischler M, et al. Dexmedetomidine and general anesthesia: a narrative literature review of its major indications for use in adults undergoing non-cardiac surgery[J]. Minerva Anestesiol, 2017, 83(12):1294~1308.
[10] 梁桦,刘洪珍,王汉兵,等.右美托咪定对结肠癌根治术病人围术期细胞免疫功能和血循环微转移的影响[J].中华麻醉学杂志,2012,32(10):1165~1168.
2018, Vol. 24 
冀公网安备13080202000677号